Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C

Louis Letendre, Pierre Noel, William L. White, Ayalew Tefferi, Mark R Litzow, Chin Yang Li, Georgene Schroeder

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Thirty patients with high-risk myelodysplastic syndrome, defined as>5% bone marrow blasts, were treated with a combination of oral all-trans-retinoic acid (45 mg/m2 daily) and subcutaneous AraC (10 mg/m2) on days 1-14 of each 28-35 day cycle repeated for 2-6 cycles. Complete remission lasting 9, 12, and 15 months was achieved in three patients. Partial and minor response did not translate into meaningful clinical improvement, like complete responders. Overall incidence of leukemia transformation and survival of this cohort of patients was no different from the expected outcome for a group of patients with similar characteristics. Copyright (C) 1999 Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)811-815
Number of pages5
JournalLeukemia Research
Volume23
Issue number9
DOIs
StatePublished - Sep 1999

Fingerprint

Myelodysplastic Syndromes
Cytarabine
Tretinoin
Therapeutics
Leukemia
Bone Marrow
Survival
Incidence

Keywords

  • Chemotherapy
  • Leukemia
  • Myelodysplastic syndrome
  • Treatment

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C. / Letendre, Louis; Noel, Pierre; White, William L.; Tefferi, Ayalew; Litzow, Mark R; Li, Chin Yang; Schroeder, Georgene.

In: Leukemia Research, Vol. 23, No. 9, 09.1999, p. 811-815.

Research output: Contribution to journalArticle

Letendre, Louis ; Noel, Pierre ; White, William L. ; Tefferi, Ayalew ; Litzow, Mark R ; Li, Chin Yang ; Schroeder, Georgene. / Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C. In: Leukemia Research. 1999 ; Vol. 23, No. 9. pp. 811-815.
@article{863e69678d6c47f7ac3daaf7a4e1b30f,
title = "Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C",
abstract = "Thirty patients with high-risk myelodysplastic syndrome, defined as>5{\%} bone marrow blasts, were treated with a combination of oral all-trans-retinoic acid (45 mg/m2 daily) and subcutaneous AraC (10 mg/m2) on days 1-14 of each 28-35 day cycle repeated for 2-6 cycles. Complete remission lasting 9, 12, and 15 months was achieved in three patients. Partial and minor response did not translate into meaningful clinical improvement, like complete responders. Overall incidence of leukemia transformation and survival of this cohort of patients was no different from the expected outcome for a group of patients with similar characteristics. Copyright (C) 1999 Elsevier Science Ltd.",
keywords = "Chemotherapy, Leukemia, Myelodysplastic syndrome, Treatment",
author = "Louis Letendre and Pierre Noel and White, {William L.} and Ayalew Tefferi and Litzow, {Mark R} and Li, {Chin Yang} and Georgene Schroeder",
year = "1999",
month = "9",
doi = "10.1016/S0145-2126(99)00095-8",
language = "English (US)",
volume = "23",
pages = "811--815",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C

AU - Letendre, Louis

AU - Noel, Pierre

AU - White, William L.

AU - Tefferi, Ayalew

AU - Litzow, Mark R

AU - Li, Chin Yang

AU - Schroeder, Georgene

PY - 1999/9

Y1 - 1999/9

N2 - Thirty patients with high-risk myelodysplastic syndrome, defined as>5% bone marrow blasts, were treated with a combination of oral all-trans-retinoic acid (45 mg/m2 daily) and subcutaneous AraC (10 mg/m2) on days 1-14 of each 28-35 day cycle repeated for 2-6 cycles. Complete remission lasting 9, 12, and 15 months was achieved in three patients. Partial and minor response did not translate into meaningful clinical improvement, like complete responders. Overall incidence of leukemia transformation and survival of this cohort of patients was no different from the expected outcome for a group of patients with similar characteristics. Copyright (C) 1999 Elsevier Science Ltd.

AB - Thirty patients with high-risk myelodysplastic syndrome, defined as>5% bone marrow blasts, were treated with a combination of oral all-trans-retinoic acid (45 mg/m2 daily) and subcutaneous AraC (10 mg/m2) on days 1-14 of each 28-35 day cycle repeated for 2-6 cycles. Complete remission lasting 9, 12, and 15 months was achieved in three patients. Partial and minor response did not translate into meaningful clinical improvement, like complete responders. Overall incidence of leukemia transformation and survival of this cohort of patients was no different from the expected outcome for a group of patients with similar characteristics. Copyright (C) 1999 Elsevier Science Ltd.

KW - Chemotherapy

KW - Leukemia

KW - Myelodysplastic syndrome

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0032780477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032780477&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(99)00095-8

DO - 10.1016/S0145-2126(99)00095-8

M3 - Article

VL - 23

SP - 811

EP - 815

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -